Clinical trial of efficacy and safety of ES16001 in patients with COVID-19

illustrative image

The company Genencell Co. Ltd is commencing recruitment for the clinical trial of the Efficacy and Safety of ES16001 in Patients With COVID-19.

The trial officially began on the July 5, 2021 and is planned to complete on December 31, 2023.

This is phase II/III, randomized, parallel-group, double-blind, placebo-controlled study. Patients must be at least 19 years of age (or according to the legal age for adult in each country) with confirmed mild or moderate COVID-19 tested positive with a real time reverse transcription polymerase chain reaction (RT-PCR) analysis of rhinopharynx samples. RT-PCR analysis of rhinopharynx samples must be <4 days old prior to the study enrolment

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05525182.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

Clinical trial of efficacy and safety of ES16001 in patients with COVID-19

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe